RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+49.81%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$5.42B
AUM Growth
+$5.42B
(+52%)
Cap. Flow
+$755M
Cap. Flow
% of AUM
13.95%
Top 10 Holdings %
Top 10 Hldgs %
46.89%
Holding
89
New
20
Increased
11
Reduced
36
Closed
9
Top Buys
| 1 |
ADC Therapeutics
ADCT
|
$259M |
| 2 |
BioNTech
BNTX
|
$193M |
| 3 |
IMMU
Immunomedics Inc
IMMU
|
$124M |
| 4 |
Pliant Therapeutics
PLRX
|
$111M |
| 5 |
Zentalis Pharmaceuticals
ZNTL
|
$79.8M |
Top Sells
| 1 |
Biogen
BIIB
|
$114M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$75.7M |
| 3 |
uniQure
QURE
|
$68.8M |
| 4 |
Tandem Diabetes Care
TNDM
|
$56.7M |
| 5 |
Centene
CNC
|
$49M |
Sector Composition
| 1 | Healthcare | 93.05% |
| 2 | Industrials | 1.02% |
| 3 | Financials | 0.23% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sanofi
SNY
$121B
| $62.6M | 1.16% | +1,225,500 | New | +$62.6M |
|
27
Stoke Therapeutics
STOK
$1.08B
| $59.6M | 1.1% | 2,502,306 +336,368 | +16% | +$8.02M |
|
|
NVRO
28
DELISTED
NEVRO CORP.
NVRO
| $59.5M | 1.1% | 497,764 -208,662 | -30% | -$24.9M |
|
29
Krystal Biotech
KRYS
$4.27B
| $58.4M | 1.08% | 1,409,745 +357,945 | +34% | +$14.8M |
|
|
TCDA
30
DELISTED
Tricida, Inc. Common Stock
TCDA
| $58.2M | 1.08% | 2,119,000 -7,600 | -0.4% | -$209K |
|
|
31
uniQure
QURE
$896M
| $56.2M | 1.04% | 1,247,135 -1,526,390 | -55% | -$68.8M |
|
|
IMGN
32
DELISTED
Immunogen Inc
IMGN
| $55.2M | 1.02% | 12,006,979 -4,726,900 | -28% | -$21.7M |
|
33
CryoPort
CYRX
$444M
| $55M | 1.02% | 1,817,663 | – | – |
|
34
Scholar Rock
SRRK
$3.14B
| $52.4M | 0.97% | 2,875,889 -14,200 | -0.5% | -$259K |
|
|
PPD
35
DELISTED
PPD, Inc. Common Stock
PPD
| $51.8M | 0.96% | 1,933,473 +642,641 | +50% | +$17.2M |
|
|
AMED
36
DELISTED
Amedisys
AMED
| $44.9M | 0.83% | 226,165 +48,600 | +27% | +$9.65M |
|
37
Dynavax Technologies
DVAX
$1.19B
| $44.9M | 0.83% | +5,062,100 | New | +$44.9M |
|
|
38
Biogen
BIIB
$19.4B
| $43.4M | 0.8% | 162,300 -427,000 | -72% | -$114M |
|
|
AXNX
39
DELISTED
Axonics, Inc. Common Stock
AXNX
| $41.9M | 0.77% | 1,192,100 -315,300 | -21% | -$11.1M |
|
40
Merck
MRK
$210B
| $40.5M | 0.75% | 524,300 -264,200 | -34% | -$20.4M |
|
41
DexCom
DXCM
$29.5B
| $39.4M | 0.73% | 97,300 -32,000 | -25% | -$13M |
|
42
Novartis
NVS
$245B
| $38.4M | 0.71% | 439,800 -213,800 | -33% | -$18.7M |
|
43
ICU Medical
ICUI
$3.15B
| $37.1M | 0.69% | +201,400 | New | +$37.1M |
|
44
Genmab
GMAB
$15.3B
| $35.8M | 0.66% | 1,057,393 -491,607 | -32% | -$16.7M |
|
45
Boston Scientific
BSX
$156B
| $31.5M | 0.58% | +897,355 | New | +$31.5M |
|
46
UnitedHealth
UNH
$281B
| $30.6M | 0.57% | 103,900 -137,200 | -57% | -$40.5M |
|
|
CTLT
47
DELISTED
CATALENT, INC.
CTLT
| $30.3M | 0.56% | 413,100 -93,200 | -18% | -$6.83M |
|
|
LMNX
48
DELISTED
Luminex Corp
LMNX
| $29.9M | 0.55% | +917,907 | New | +$29.9M |
|
|
EIDX
49
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $28.3M | 0.52% | 593,842 -95,636 | -14% | -$4.56M |
|
50
Zymeworks
ZYME
$1.12B
| $28.3M | 0.52% | 783,500 -85,100 | -10% | -$3.07M |
|